Concepedia

Publication | Closed Access

Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma

DOI

166

Citations

8

References

2011

Year

Jean Bousquet, Zenon Siergiejko, Ewa Świebocka, Marc Humbert, Klaus F. Rabe, Nicola J. Smith, Janna C. Leo, Clare Peckitt, Robert Maykut, Guy Peachey
Allergy

Abstract

Response to omalizumab, as assessed by a physician's GETE at 16 weeks, is an effective predictor of continuing persistent response to omalizumab for the majority of patients.

References

YearCitations

Page 1